sotatercept

Pharma

Merck preps filings after Winrevair succeeds in severe PAH study

Eight months after snaring a first FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition.

Fraiser Kansteiner Nov 25, 2024 9:00am

As Gardasil sales fall in China, Merck has few answers why

Jul 30, 2024 11:53am

Merck touts newly approved Winrevair as example of BD acumen

Apr 25, 2024 11:06am

FDA signs off on Merck’s potential blockbuster Winrevair for PAH

Mar 26, 2024 5:11pm

FDA approves Johnson & Johnson's combo pill Opsynvi for PAH

Mar 25, 2024 11:05am

After recent moves, Merck no longer focused on Keytruda deadline

Apr 27, 2023 1:22pm